PepGen (PEPG) News Today → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free PEPG Stock Alerts $14.50 -0.06 (-0.41%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 22, 2024 | finance.yahoo.comWe're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn RateMay 19, 2024 | americanbankingnews.comNiels Svenstrup Sells 10,000 Shares of PepGen Inc. (NASDAQ:PEPG) StockMay 19, 2024 | americanbankingnews.comPepGen's (PEPG) "Buy" Rating Reaffirmed at HC WainwrightMay 19, 2024 | americanbankingnews.comPepGen (NASDAQ:PEPG) Earns Outperform Rating from WedbushMay 18, 2024 | insidertrades.comInsider Selling: PepGen Inc. (NASDAQ:PEPG) SVP Sells 10,000 Shares of StockMay 18, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for PepGen Inc. (NASDAQ:PEPG) Issued By WedbushMay 18, 2024 | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for PepGen Inc. (NASDAQ:PEPG)May 18, 2024 | americanbankingnews.comBrokers Offer Predictions for PepGen Inc.'s Q2 2024 Earnings (NASDAQ:PEPG)May 17, 2024 | marketbeat.comPepGen Inc. (NASDAQ:PEPG) SVP Niels Svenstrup Sells 10,000 SharesPepGen Inc. (NASDAQ:PEPG - Get Free Report) SVP Niels Svenstrup sold 10,000 shares of PepGen stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $13.41, for a total value of $134,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.May 17, 2024 | marketbeat.comPepGen Inc. to Post Q2 2024 Earnings of ($0.71) Per Share, HC Wainwright Forecasts (NASDAQ:PEPG)PepGen Inc. (NASDAQ:PEPG - Free Report) - HC Wainwright decreased their Q2 2024 earnings per share estimates for PepGen in a report released on Wednesday, May 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.71) per share for the quarter, down from theirMay 16, 2024 | marketbeat.comPepGen Inc. (NASDAQ:PEPG) Forecasted to Post FY2028 Earnings of $0.88 Per SharePepGen Inc. (NASDAQ:PEPG - Free Report) - Analysts at HC Wainwright upped their FY2028 earnings estimates for shares of PepGen in a report issued on Wednesday, May 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $0.88 for the year, up from their prMay 15, 2024 | markets.businessinsider.comBuy Rating on PepGen Inc. Backed by PGN-EDO51’s Efficacy and Safety ProfileMay 15, 2024 | marketbeat.comPepGen (NASDAQ:PEPG) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $26.00 price objective on shares of PepGen in a research report on Wednesday.May 14, 2024 | msn.comPEPG Stock Earnings: PepGen Beats EPS for Q1 2024May 14, 2024 | globenewswire.comPepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 9, 2024 | msn.comHHS panel to vote in Nov. on DMD screening for newbornsMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval ProspectsApril 26, 2024 | markets.businessinsider.comOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label ExpansionApril 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreApril 1, 2024 | marketbeat.comPepGen Inc. (NASDAQ:PEPG) Sees Large Growth in Short InterestPepGen Inc. (NASDAQ:PEPG - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 260,400 shares, an increase of 21.8% from the February 29th total of 213,800 shares. Approximately 1.3% of the company's shares are sold short. Based on an average trading volume of 128,100 shares, the days-to-cover ratio is presently 2.0 days.March 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)March 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Increases Position in PepGen Inc. (NASDAQ:PEPG)Adage Capital Partners GP L.L.C. lifted its position in PepGen Inc. (NASDAQ:PEPG - Free Report) by 18.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 680,000 shares of the company'sMarch 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | marketbeat.comWedbush Weighs in on PepGen Inc.'s FY2028 Earnings (NASDAQ:PEPG)PepGen Inc. (NASDAQ:PEPG - Free Report) - Analysts at Wedbush issued their FY2028 earnings estimates for shares of PepGen in a note issued to investors on Wednesday, March 6th. Wedbush analyst L. Chico expects that the company will earn ($0.49) per share for the year. Wedbush has a "Outperform"March 7, 2024 | marketbeat.comPepGen (NASDAQ:PEPG) Price Target Lowered to $20.00 at WedbushWedbush decreased their price target on PepGen from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Thursday.March 7, 2024 | marketbeat.comFmr LLC Lowers Holdings in PepGen Inc. (NASDAQ:PEPG)Fmr LLC decreased its stake in PepGen Inc. (NASDAQ:PEPG - Free Report) by 13.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,365,965 shares of the company's stock after selling 377,985 shares during the quarter. FmMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyFebruary 24, 2024 | marketbeat.comRathbones Group PLC Makes New $315,000 Investment in PepGen Inc. (NASDAQ:PEPG)Rathbones Group PLC purchased a new position in shares of PepGen Inc. (NASDAQ:PEPG - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 62,003 shares of the company's stock, valued at approximately $315,000. RFebruary 21, 2024 | msn.comFDA grants fast track to PepGen’s DM1 treatmentFebruary 20, 2024 | markets.businessinsider.comPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1February 20, 2024 | finance.yahoo.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 20, 2024 | globenewswire.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 8, 2024 | msn.comPepGen Inc. Secures Funding to Advance Research ProgramsFebruary 8, 2024 | msn.comPepGen Inc. Announces Pricing for Its OfferingFebruary 7, 2024 | tmcnet.comPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockFebruary 7, 2024 | marketwatch.comPepGen Stock Higher After Follow-on OfferingFebruary 6, 2024 | msn.comPepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 dataFebruary 6, 2024 | marketbeat.comPepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 dataPepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapyFebruary 2, 2024 | markets.businessinsider.comTop 4 Health Care Stocks That May Crash This QuarterJanuary 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO PlatformJanuary 30, 2024 | msn.comPepGen stock soars after rival Sarepta reports data for DMD drugJanuary 30, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for PepGen (NASDAQ:PEPG)Wedbush restated an "outperform" rating and issued a $21.00 price objective on shares of PepGen in a research report on Tuesday. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Three basic steps to building the Ultimate Dividend Portfolio. (Ad)There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will. Click here to get them (for Free). PEPG Media Mentions By Week PEPG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PEPG News Sentiment▼1.340.87▲Average Medical News Sentiment PEPG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PEPG Articles This Week▼31▲PEPG Articles Average Week Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Esperion Therapeutics News Annexon News Theravance Biopharma News Neurogene News Verve Therapeutics News Adlai Nortye News Korro Bio News Acelyrin News Mereo BioPharma Group News Fulcrum Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PEPG) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.